Toward the Simplification of Antithrombotic Treatment of Venous Thromboembolism
Authors: Paolo Prandoni
Journal: Annals of Internal Medicine (2004)

Editorials1 June 2004Toward the Simplification of Antithrombotic Treatment of Venous ThromboembolismPaolo Prandoni, MD, PhDPaolo Prandoni, MD, PhDFrom University of Padua, 35128 Padua, Italy.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-11-200406010-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail For almost half a century, physicians have treated noncritical patients who have acute venous thromboembolism with adjusted doses of unfractionated heparin or, more recently, fixed doses of low-molecular-weight heparin (LMWH), followed by oral warfarin for variable periods. Although both forms of heparin are safe and effective therapies to prevent recurrent venous thromboembolism (1), physicians are increasingly using LMWHs because of their longer half-life, more predictable pharmacologic effects, and convenience. The subcutaneous administration of fixed doses, adjusted only to body weight, is straightforward even outside the hospital. Despite convincing evidence that LMWH is a safe and effective treatment of venous thromboembolism ...References1. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130:800-9. [PMID: 10366369] LinkGoogle Scholar2. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al . Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996;334:682-7. [PMID: 8594426] CrossrefMedlineGoogle Scholar3. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al . A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-81. [PMID: 8594425] CrossrefMedlineGoogle Scholar4. Haverkamp D, Hutten BA, Büller HR, Gallus AS, Lensing AW, Prins MH. The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism. J Thromb Haemost. 2003;1:69-73. [PMID: 12871541] CrossrefMedlineGoogle Scholar5. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833-40. [PMID: 12196081] CrossrefMedlineGoogle Scholar6. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Ann Intern Med. 2004;140:867-73. LinkGoogle Scholar7. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al . Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695-702. [PMID: 14585937] CrossrefMedlineGoogle Scholar8. Büller HR. Factor Xa is a superior target to factor IIa for antithrombotic therapies. Semin Thromb Hemost. 2003;29 Suppl 1 37. [PMID: 14730477] CrossrefMedlineGoogle Scholar9. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-9. [PMID: 1406880] CrossrefMedlineGoogle Scholar10. Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M, et al . Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-5. [PMID: 1346817] CrossrefMedlineGoogle Scholar11. Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, et al . A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost. 2003;1:41-7. [PMID: 12871538] CrossrefMedlineGoogle Scholar12. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost. 2004;2:47-53. [PMID: 14717965] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Paolo Prandoni, MD, PhDAffiliations: From University of Padua, 35128 Padua, Italy.Disclosures: None disclosed.Corresponding Author: Paolo Prandoni, MD, PhD, Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University Hospital of Padua, via Ospedale Civile 105, 35128 Padua, Italy; e-mail, [email protected]it. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis Harry R. Büller , Bruce L. Davidson , Hervé Decousus , Alexander Gallus , Michael Gent , Franco Piovella , Martin H. Prins , Gary Raskob , Annelise E.M. Segers , Roger Cariou , Oscar Leeuwenkamp , and Anthonie W.A. Lensing , and The Matisse Investigators* Metrics Cited byPlasmin and Matrix Metalloproteinase System in Deep Venous Thrombosis ResolutionHow I treat venous thromboembolism in patients with cancerSevere Chronic Venous Insufficiency: Magnitude of the Problem and ConsequencesThe Role of Inflammation in Early and Late Venous Thrombosis: Are There Clinical Implications?Emerging strategies for treatment of venous thromboembolismWat is de plaats van fondaparinux? 1 June 2004Volume 140, Issue 11Page: 925-926KeywordsHemorrhageHeparinHospital medicineLow molecular weight heparinPatientsPulmonary embolismResearch laboratoriesThrombinTotal hip arthroplastyVenous thromboembolism ePublished: 1 June 2004 Issue Published: 1 June 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...